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BirA is a bifunctional E. coli protein that acts as a repressor of biotin (bio) operon expression and as an enzyme that covalently
attaches biotin to its cognate acceptor proteins. The mechanism of operon repression requires BirA dimerization triggered by
BirA-catalyzed synthesis of biotinoyl-adenylate (bio-AMP). The postulated model suggests that an unmodified acceptor
protein binds themonomeric BirA:bio-AMP complex and thereby blocks assembly (dimerization) of the form of BirA that binds
DNA. Here, Solbiati and Cronan test this proposal and, based on their findings, argue that the regulatory switch does not
require the extensive protein-protein interactions proposed to play a critical role in the current model.A Client-Selective Hsp90 Inhibitor
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Hsp90 has pivotal roles in multi-organ physiology and pathology. So far, almost all
known Hsp90 inhibitors are known to bind to the Hsp900s N-terminal ATP-binding
site and simultaneously induce degradation/activation of its multiple client proteins.
Here, Kimura et al. describe the characterization of ITZ-1, a small molecule inhibitor
of Hsp90 with client selective property. Within the Hsp90 client proteins, ITZ-1 strongly
induced heat shock factor-1 (HSF1) activation and caused mild Raf-1 degradation, but
scarcely induced degradation of a broad range of Hsp90 client proteins by binding to the
Hsp90 C terminus. ITZ-1 may be useful as a cytoprotective agent.Antifungal Phosphonate Oligopeptides Biosynthesis
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The gene cluster from Bacillus subtilis ATCC6633 responsible for biosynthesis of the phosphonate antibiotic rhizocticin was
identified and characterized by Borisova et al. using a combination of biochemistry, genetics, and molecular biology. Expres-
sion of these genes in a heterologous host led to production of the desired antibiotic. In vitro biochemical experiments showed
that an early step in the biosynthetic pathway involves an unusual aldol reaction between phosphonoacetaldehyde and oxalo-
acetate catalyzed by an aldolase homolog, RhiG. This transformation provides a new biosynthetic route to structurally diverse
phosphonate natural products.The Microarray Bead Game
PAGE 38Several approaches have been developed for screening combinatorial
libraries or collections of synthetic molecules for agonists or antagonists of
protein function, each with its own advantages and limitations. In this report,
Astle et al. describe an experimental platform that seamlessly couples
massively parallel bead-based screening of one bead–one compound com-
binatorial libraries with microarray-based quantitative comparisons of the
binding affinities of the many hits isolated from the bead library. Combined
with other technical improvements, this technique allows the rapid identifica-
tion of the best protein ligands in combinatorial libraries containing millions of
compounds without the need for labor-intensive resynthesis of the hits.Small Molecules to the Rescue: Oncogenic p53
Mutant
PAGE 46Small molecules that bind to and rescue the function of mutant p53 have broad implications as anticancer therapeutics. The
p53 cancer mutation Y220C presents a unique opportunity to target mutant p53 due to the mutation-induced formation of
a surface cavity that can accommodate stabilizing small molecules. Results obtained by Basse et al. paint a clear picture
of how a drug-like molecule could dock within the mutational cavity of the Y220C mutant. In this way, the findings provide
the framework for the rational design of lead ligands that rescue the transcriptional activity of the oncogenic p53-Y220C
by selectively targeting the mutation site.Chemistry & Biology 17, January 29, 2010 ª2010 Elsevier Ltd All rights reserved ix
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FR-900098 is a potent chemotherapeutic agent for the treatment of malaria. Here, Johannes et al. produced this compound in
a recombinant E. coli strain and elucidated the biosynthetic mechanisms. The authors uncovered an unprecedented func-
tional role of nucleotide conjugation in natural product biosynthesis. In addition, they discovered that the biosynthetic route
for phosphonic acid antibiotic, FR-33289, is embedded in the FR-900098 biosynthetic route. These studies now open the
possibilities for metabolic engineering in E. coli to increase production of the antimalarial antibiotic and combinatorial biosyn-
thesis to generate novel derivatives of FR-900098 with more potent antimalarial activity.Inhibit‘‘ING’’ Deacetylasesx Chemistry & Biology 17, January 29, 2010 ª201PAGE 65
Deacetylase inhibitors are promising therapeutics for several diseases,
including cancers and neurodegenerative diseases. These drugs are known
to inhibit deacetylase activity by targeting the catalytic site. Here, Smith
et al. find that these small molecule inhibitors can also disrupt critical
protein-protein interactions within multisubunit deacetylase complexes and,
through this, alter chromatin targeting of the deacetylases. This suggests
that deacetylase inhibitors use multiple avenues to disrupt deacetylase
activity.Heavy Metals in NRF2 Signaling Pathway
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Transcription factor NF-E2 p45-related factor 2 (Nrf2) mediates adaptation to
oxidants and electrophiles through upregulating genes that contain antioxi-dant response elements (ARE) in their promoters. Using the stably transfected human AREc32 reporter cell line, Wang
et al. found that copper and other transition metals enhanced induction of ARE-driven luciferase by 2-tert-butyl-1,4-hydro-
quinone (tBHQ) due to increased oxidation to 2-tert-butyl-1,4-benzoquinone (tBQ). Compounds which share para- or
ortho-hydroquinone structure, such as catechol estrogens, dopamine, and L-DOPA, also induce ARE-driven luciferase in
a Cu2+-dependent manner. Thus, the oxidation of para- and ortho-hydroquinones to quinones represents the rate-limiting
step in the activation of Nrf2 and may account for a significant portion of their biological effects.TB: Seeking Help!
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Methionine aminopeptidase (MetAP) is a metalloprotease that removes the N-terminal methionine during protein synthesis.
To assess the importance of the twoMetAPs inM. tuberculosis, Olaleye et al. overexpressed and purified each of the MetAPs
to near homogeneity and characterized them in vitro. The authors screened a library of 175,000 compounds against
MtMetAP1c and identified inhibitors of both MtMetAPs. It was found that the MtMetAP inhibitors were active against
M. tuberculosis. Knockdown of MtMetAP1a, but not MtMetAP1c, resulted in decreased viability of M. tuberculosis. These
results suggest that MtMetAP1a is a promising target for developing antituberculosis agents.0 Elsevier Ltd All rights reserved
